Effect of Biofield Energy Treatment on Streptococcus group B: A Postpartum Pathogen

Abstract

Streptococcus agalactiae group B (S. agalactiae gr. B) is widespread in nature mainly causes bacterial septicemia and neonatal meningitis. The current study was attempted to investigate the effect of biofield treatment on S. agalactiae gr. B with respect of antimicrobial sensitivity, biochemical reactions and bio typing. S. agalactiae gr. B strain was used in this experiment bearing the American Type Culture Collection (ATCC 12386) number and stored according to the recommended storage protocol. The revived and lyophilized state of ATCC strains of S. agalactiae gr. B were selected for the study. Gr. I was considered as control. Both revived (Group; Gr. II) and lyophilized (Gr. III) strains of S. agalactiae gr. B were subjected to Mr. Trivedi’s biofield treatment. Gr. II was assessed on day 5 and day 10 while Gr. III on day 10 with respect to the control (Gr. I) using MicroScan Walk-Away® system. Although biofield treatment did not show any change with respect to susceptibility pattern. However the minimum inhibitory concentration of S. agalactiae gr. B showed significant (70.37%) alteration, out of twenty-seven tested antimicrobials, among which in Gr. II i.e. 62.96% on day 5 and 66.67% on day 10 while no alteration was found in lyophilized group (Gr. III) as compared to the control. Moreover, the improvement of MIC value of norfloxacin was observed by two-fold (8 to ≤4 µg/mL) in Gr. II on day 10 after biofield energy treatment as compared to the control. It was observed that overall 48.28% biochemical reactions, out of twenty-nine were altered in Gr. II with respect to the control. Moreover, biotype numbers were changed in Gr. II on day 5 (777777615) and on day 10 (757677405) as compared to the control (237147047). The results suggest that biofield treatment has significant impact on S. agalactiae gr. B in revived treated cells (Gr. II) with respect to MIC values, biochemical reactions pattern and biotype number.

Full text

Volume 7(5): 269-273 (2015) - 269
J Microb Biochem Technol
ISSN: 1948-5948 JMBT, an open access journal
Research Article Open Access
Trivedi et al., J Microb Biochem Technol 2015, 7:5
http://dx.doi.org/10.4172/1948-5948.1000223
Research Article
Open Access
Microbial & Biochemical Technology
*Corresponding author: Snehasis Jana, Trivedi Global Inc., 10624 S Eastern
Avenue Suite A-969, Henderson, NV 89052, USA, Tel: +91-755-6660006; E-mail:
publication@trivedisrl.com
Received August 12, 2015; Accepted September 01, 2015; Published September
08, 2015
Citation: Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, et al. (2015)
Effect of Bioeld Energy Treatment on Streptococcus group B: A Postpartum
Pathogen. J Microb Biochem Technol 7: 269-273. doi:10.4172/1948-5948.1000223
Copyright: © 2015 Trivedi MK, et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Abstract
Streptococcus agalactiae group B (S. agalactiae gr. B) is widespread in nature mainly causes bacterial
septicemia and neonatal meningitis. The current study was attempted to investigate the effect of bioeld treatment
on S. agalactiae gr. B with respect of antimicrobial sensitivity, biochemical reactions and bio typing. S. agalactiae
gr. B strain was used in this experiment bearing the American Type Culture Collection (ATCC 12386) number
and stored according to the recommended storage protocol. The revived and lyophilized state of ATCC strains
of S. agalactiae gr. B were selected for the study. Gr. I was considered as control. Both revived (Group; Gr. II)
and lyophilized (Gr. III) strains of S. agalactiae gr. B were subjected to Mr. Trivedi’s bioeld treatment. Gr. II was
assessed on day 5 and day 10 while Gr. III on day 10 with respect to the control (Gr. I) using MicroScan Walk-Away
®
system. Although bioeld treatment did not show any change with respect to susceptibility pattern. However the
minimum inhibitory concentration of S. agalactiae gr. B showed signicant (70.37%) alteration, out of twenty-seven
tested antimicrobials, among which in Gr. II i.e. 62.96% on day 5 and 66.67% on day 10 while no alteration was found
in lyophilized group (Gr. III) as compared to the control. Moreover, the improvement of MIC value of noroxacin was
observed by two-fold (8 to ≤4 µg/mL) in Gr. II on day 10 after bioeld energy treatment as compared to the control.
It was observed that overall 48.28% biochemical reactions, out of twenty-nine were altered in Gr. II with respect to
the control. Moreover, biotype numbers were changed in Gr. II on day 5 (777777615) and on day 10 (757677405)
as compared to the control (237147047). The results suggest that bioeld treatment has signicant impact on S.
agalactiae gr. B in revived treated cells (Gr. II) with respect to MIC values, biochemical reactions pattern and biotype
number.
Effect of Biofield Energy Treatment on
Streptococcus
group B: A
Postpartum Pathogen
Mahendra Kumar Trivedi
1
, Alice Branton
1
, Dahryn Trivedi
1
, Gopal Nayak
1
, Harish Shettigar
1
, Sambhu Charan Mondal
2
and Snehasis Jana
2
*
1
Trivedi Global Inc., 10624 S Eastern Avenue Suite A-969, Henderson, NV 89052, USA
2
Trivedi Science Research Laboratory Pvt. Ltd., Hall-A, Chinar Mega Mall, Chinar Fortune City, Madhya Pradesh, India
Keywords: Streptococcus agalactiae group B; Bioeld treatment;
Minimum inhibitory concentration; Biochemical reaction; Biotype
Abbreviations: CLSI: Clinical and laboratory standards institute;
GBS: Group B Streptococci; CAMP: Christie-Atkins-Munch-Petersen;
CDC: Centers for Disease Control and Prevention; ACOG: American
College of Obstetricians and Gynecologists; AAP: American Academy
of Pediatrics; MIC: Minimum inhibitory concentration; ATCC:
American Type Culture Collection; PBPC 20: Positive Breakpoint
Combo 20
Introduction
Group B Streptococci (GBS), or Streptococcus agalactiae group B,
are Gram-positive, non-spore forming, non-motile, β-hemolytic and
chain-forming cocci bacteria. It is mainly inhabitant in human gut ora
and female urogenital tract [1]. Pregnant women [2] and neonates [3] are
the main victim host of this organism. It can be transferred to neonates
through the birth canal and causes bacterial septicaemia and neonatal
meningitis [4]. Most of GBS, produce Christie-Atkins-Munch-Petersen
(CAMP) factor or protein B an extracellular cytolytic protein and
β-lysin from Staphyllococcus species are jointly lysed the erythrocytes
[5]. It is estimated that in US over 70,000 cases of GBS diseases
were prevented [6]. Several antibiotics such as penicillin, ampicillin,
amoxicillin, cephalosporins (all three generations), macrolides,
clindamycin and vancomycin (as alternative) have been used to treat
against GBS infections. Among above mentioned antibiotics penicillin
is the drug of choice next to cefazolin. However, it also have certain
limitations such as high minimum inhibitory concentration (MIC), a
factor associated with high level of bacteremia and more concentration
of microbes in tissue, especially in cerebrospinal uid [7,8]. erefore,
some alternative treatment strategies are needed to overcome these
lacunas against β-hemolytic strain of gr. B Streptococci. Bioeld
treatment has been known as an alternative approach that may be
useful for S. agalactiae group B infected patients.
Researchers have shown that short-lived electrical events or action
potential exist in the several type of mammalian cells such as neurons,
muscles, and endocrine cells [9]. For instance, when the cells present
in central nervous system of human body communicate with each
another by means of electrical signals that propagate along the nerve
impulses. erefore, it was hypothesized that bioeld exists around
the human body and evidence was found using electromyography,
electrocardiography and electroencephalogram [10]. us, the human
body emits the electromagnetic waves in the form of bio-photons,
which surrounds the body and it is commonly known as bioeld.
erefore, the bioeld consists of electromagnetic eld, being generated
by moving electrically charged particles (ions, cell, molecule etc.) inside
the human body. Rivera-Ruiz reported that electrocardiography has
been extensively used to measure the bioeld of human body [11].
us, human has the ability to harness the energy from environment or
Universe and can transmit into any living or nonliving object(s) around
the Globe. e objects always receive the energy and responding into
useful way that is called bioeld energy and the process is known as

Citation: Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, et al. (2015) Effect of Bioeld Energy Treatment on Streptococcus group B: A
Postpartum Pathogen. J Microb Biochem Technol 7: 269-273. doi:10.4172/1948-5948.1000223
Volume 7(5): 269-273 (2015) - 270
J Microb Biochem Technol
ISSN: 1948-5948 JMBT, an open access journal
bioeld treatment that is also called as Trivedi eect
®
. Mr. Trivedi’s
unique bioeld treatment has been known to transform the structural,
physical, and thermal properties of several metals in material science
[12-14], improved the overall productivity of crops [15,16], altered
characteristics features of microbes [17-19] and improved growth and
anatomical characteristics of various medicinal plants [20,21].
Due to the clinical signicance of this organism and literature
reports on bioeld treatment, the present work was undertaken to
evaluate the impact of bioeld treatment on S. agalactiae group B
in relation to antimicrobials susceptibility and bio typing based on
various biochemical characters.
Materials and Methods
S. agalactiae group B, American Type Culture Collection (ATCC
12386) strains were procured from MicroBioLogics, Inc., USA, in
two sets A and B. Two dierent sealed packs were stored with proper
storage conditions until further use. All the tested antimicrobials and
biochemicals were procured from Sigma-Aldrich, MA, USA. e
antimicrobial susceptibility, biochemical reactions and biotype number
were estimated with the help of MicroScan Walk-Away
®
(Dade Behring
Inc., West Sacramento, CA, USA) using Positive Breakpoint Combo 20
(PBPC 20) panel with respect to the control group.
Experimental design
Two ATCC samples A and B of S. agalactiae gr. B were grouped
(Gr.). ATCC A sample was revived and divided into two parts Gr.I
(control) and Gr.II (revived); likewise, ATCC B was labeled as Gr.III
(lyophilized).
Bioeld treatment strategy
e Gr. I remained as untreated. e treatment Gr. II and III
in sealed pack were handed over to Mr. Trivedi for bioeld energy
treatment under laboratory condition. Mr. Trivedi provided the
treatment through his energy transmission process which includes
bioenergy emission to the treated groups (Gr. II and Gr. III) without
touching the samples. Aer treatment, sample was handed over in the
same condition and stored at standard conditions as per the standard
experimental protocol. An optimum precautionary measure were taken
while evaluating the study parameters throughout the experiments.
e dierences in parameters before and aer the treatment were
noted and compared. Gr.II was assessed at two time point i.e. on day
5 and day 10, while Gr. III was assessed on day 10 for antimicrobial
susceptibility, MIC, biochemical reactions pattern, and biotyping.
Antimicrobial susceptibility test
Investigation of antimicrobial susceptibility of S. agalactiae gr. B
was carried out with the help of automated instrument, MicroScan
Walk-Away
®
system using PBPC 20 panel as per the clinical and
laboratory standards institute (CLSI) guidelines. e test was carried
out on MicroScan, which was miniaturized of the broth dilution
susceptibility test that has been dehydrated. Briey, the standardized
suspension of S. agalactiae gr. B was inoculated, rehydrated, and then
subjected to incubation for 16 hours at 35°C. e detailed experimental
procedures and conditions were followed as per the manufacturer's
instructions. e antimicrobial susceptibility pattern and MIC were
determined by observing the lowest antimicrobial concentration
showing growth inhibition [22].
Biochemical reaction studies
Biochemical reactions of S. agalactiae gr. B were determined using
MicroScan Walk-Away
®
, system with PBPC 20 panel [22]. Biochemicals
used in the study were arabinose, arginine, bacillosamine, bile
esculin, β-lactamases, crystal violet, hemolysin, indoxyl phosphatase,
inulin, acidication lactose, mannitol, mannose, micrococcus screen,
sodium chloride, nitrate, novobiocin, optochin, p-nitro phenyl β-D-
glucuronide, p-nitro phenyl β-D-galactopyranoside, phosphatase,
pyruvate, pyrolidonyl arylamidase, ranose, rambose, sorbitol,
thymidine free growth, acidication trehalose, urea, and Voges-
Proskauer.
Identication of organism by biotype number
e biotype number of S. agalactiae gr. B was determined on
MicroScan Walk-Away
®
processed panel data report with the help of
biochemical reactions data [22].
Results and Discussion
Antimicrobial susceptibility test
e outcomes of MIC values of tested antimicrobials against S.
agalactiae gr. B aer bioeld treatment are summarized in Table 1. e
data were analyzed using automated system and compared with respect
to the control. In this experiment, twelve antibiotics were used to
investigate the susceptibility pattern on GBS viz. ampicillin, cefepime,
cefotaxime, ceriaxone, chloramphenicol, clindamycin, levooxacin,
linezolid, ooxacin, penicillin, tetracycline, and vancomycin. Out
of these, ve antibiotics showed susceptible in the control sample. It
has been evidenced from literatures that penicillin and its derivatives
are the choice of drugs against gr. B streptococcal infection [8,9].
However, bioeld treatment did not show any alteration with respect
to susceptibility pattern in all the treated groups aer bioeld treatment
(data not shown). Besides sensitivity assay, the MIC values of tested
antimicrobials were signicantly (70.37%) altered out of twenty seven
as compared to the control. e MIC value of noroxacin was reduced
by two-fold to ≤ 4 µg/mL aer bioeld treatment in Gr. II on day 10
as compared to the control (8 µg/mL). e MIC values of cefazolin,
cephalothin, and chloramphenicol were changed from ≤ 8 to >16 µg/
mL in Gr. II on day 5 and 10 as compared to the control. e MIC values
of rifampin and synercid were changed from ≤ 1 to >2 µg/mL in Gr. II
on day 5 and 10 as compared to the control. Alteration of MIC values of
cefotaxime and ceriaxone were changed from ≤8 to 32 µg/mL in Gr.
II on day 5 and 10 as compared to the control. Moreover, MIC values
of amoxicillin/k-clavulanate and trimethoprim/sulfamethoxazole
were slightly changed from ≤4/2 to >4/2 µg/mL (on day 5 and 10) and
≤2/38 to >2/38 µg/mL (on day 5) respectively in Gr. II aer bioeld
treatment as compared to the control. Antimicrobial linezolid showed
an alteration of MIC value in Gr. II on day 5 (>4 µg/mL) and on day
10 (4 µg/mL) as compared to the control. Besides this, alteration of
MIC values were observed in case of penicillin (≤ 0.03 to >8 µg/mL),
vancomycin (≤ 0.2 to >16 µg/mL), nitrofurantoin (≤ 32 to >64 µg/mL),
clindamycin (≤ 0.5 to >2 µg/mL), ampicillin (≤ 0.25 to >8 µg/mL) and
ampicillin/sulbactam (≤ 8/4 to >16/8 µg/mL) in Gr. II on day 5 and 10
as compared to the control. e MIC value of tetracycline was changed
from ≤ 4 to 8 µg/mL in Gr. II on day 10 and MIC value of oxacillin
was changed from ≤ 0.25 to >2 µg/mL (on day 5) and 2 µg/mL on day
10 in Gr. II as compared to control. Antimicrobials did not show any
change in MIC value in Gr. III as compared to the control aer bioeld
treatment. Seventeen out of twenty seven (62.96%) antimicrobials
showed alteration of MIC value in Gr. II on day 5 and 66.67% (eighteen

Citation: Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, et al. (2015) Effect of Bioeld Energy Treatment on Streptococcus group B: A
Postpartum Pathogen. J Microb Biochem Technol 7: 269-273. doi:10.4172/1948-5948.1000223
Volume 7(5): 269-273 (2015) - 271
J Microb Biochem Technol
ISSN: 1948-5948 JMBT, an open access journal
such as ranose (RAF) and sorbitol (SOR) showed an alteration of
biochemical reaction i.e. negative (-) to positive (+) in Gr. II on day 5
while remained negative in Gr. II on day 10 and in Gr. III as compared
to the control.
e one of the key characteristic feature for GBS is complete
lysis of red blood cells and metabolization of sugars by fermentation
process. Hence, in control sample the positive reaction of hemolysin
(HEM) indicated β-hemolysis of erythrocytes and positive reaction of
acidifying lactose (LAC) indicated the production of lactic acid as bi-
product. e data was supported with literature [23]. Similarly, based
on existing literature pyrolidonyl arylamidase (PYR) has negative
reaction in group B streptococcal species while positive reaction in
group A streptococcal. Control data of PYR was well supported with
literature data [24]. However, aer bioeld treatment the negative
reaction was altered in Gr. II, assessed on day 5 as well as day 10 due to
change of enzymatic reaction.
Overall, 48.28% biochemical reactions were altered in tested
twenty-nine biochemicals with respect to the control aer bioeld
treatment. In both time points of Gr. II (day 5 and 10) 41.38% (twelve
out of twenty-nine) biochemical reactions were altered as compared
to the control. About 51.72% out of twenty-nine biochemicals, such as
arabinose (ARA), bacillosamine (BAC), β-lactamase (BL), hemolysin
(HEM), indoxyl phosphatase (IDX), inulin (INU), acidication lactose
(LAC), mannose (MNS), micrococcus screen (MS), optochin (OPT),
glycosidase (PGT), phosphatase (PHO), thymidine free growth (TFG),
acidication trehalose (TRE), and Voges-Proskauer (VP) did not
out of twenty seven) on day 10 as compared to the control aer bioeld
treatment. Eight, out of twenty seven tested antimicrobials (29.63%)
viz. cefepime, ciprooxacin, gatioxacin, imipenem, levooxacin,
moxioxacin, ooxacin and piperacillin/tazobactam did not show any
alteration of MIC values in all the treated cells of GBS as compared to
the control (Table 1).
Biochemical reactions studies
Study of biochemical reactions can be utilized to identify
the enzymatic and metabolic characteristic features of microbes.
Microorganisms can be categorically dierentiated based on their
utilization of specic biochemicals as nutrients during the process of
metabolism or enzymatic reactions. e specic biochemical showed
some changes against S. agalactiae gr. B aer bioeld treatment that
are shown in Table 2. Biochemicals such as bile esculin (BE), crystal
violet (CV), mannitol (MAN), sodium chloride (NaCl), nitrate (NIT),
novobiocin (NOV), pyrolidonyl arylamidase (PYR) and urea (URE)
were changed from negative (-) to positive (+) reactions in revived
treated group (Gr. II) on day 5 and 10, but remained same i.e. negative
(-) reaction in lyophilized treated cells (Gr. III) with respective to
control. Arginine (ARG) and glycosidase (PGR) were converted
from positive (+) to negative (-) reactions in Gr. II on day 10, while
remained unchanged i.e. positive (+) on day 5 in Gr. II and in Gr. III as
compared to the control in bioeld treated S. agalactiae gr. B. Similarly,
pyruvate (PRV), and rambose (RBS) were converted from positive (+)
to negative (-) reactions on both days in Gr. II, while did not show any
change in Gr. III as compared with the control. Moreover, biochemicals
Table 1: Effect of bioeld treatment on Streptococcus agalactiae group B to minimum inhibitory concentration (MIC) of tested antimicrobials.
S. No. Antimicrobial Type of Response
Gr. I Gr. II Gr. III
Day 5 Day 10
1. Amoxicillin/k-clavulanate ≤4/2 >4/2 >4/2 ≤4/2
2. Ampicillin/sulbactam ≤8/4 >16/8 >16/8 ≤8/4
3. Ampicillin ≤0.25 >8 >8 ≤0.25
4. Cefazolin ≤8 >16 >16 ≤8
5. Cefepime ≤8 ≤8 ≤8 ≤8
6. Cefotaxime ≤8 32 32 ≤8
7. Ceftriaxone ≤8 32 32 ≤8
8. Cephalothin ≤8 >16 >16 ≤8
9. Chloramphenicol ≤8 >16 >16 ≤8
10. Ciprooxacin ≤1 ≤1 ≤1 ≤1
11. Clindamycin ≤0.5 >2 >2 ≤0.5
12. Gatioxacin ≤2 ≤2 ≤2 ≤2
13. Imipenem ≤4 ≤4 ≤4 ≤4
14. Levooxacin ≤2 ≤2 ≤2 ≤2
15. Linezolid ≤2 >4 4 ≤2
16. Moxioxacin ≤2 ≤2 ≤2 ≤2
17. Nitrofurantoin ≤32 >64 >64 ≤32
18. Noroxacin 8 8 ≤4 8
19. Ooxacin ≤2 ≤2 ≤2 ≤2
20. Oxacillin ≤0.25 >2 2 ≤0.25
21. Penicillin ≤0.03 >8 >8 ≤0.03
22. Piperacillin/tazobactam ≤4 ≤4 ≤4 ≤4
23. Rifampin ≤1 >2 >2 ≤1
24. Synercid ≤1 >2 >2 ≤1
25. Tetracycline ≤4 ≤4 8 ≤4
26. Trimethoprim/sulfamethoxazole ≤2/38 >2/38 ≤2/38 ≤2/38
27. Vancomycin ≤2 >16 >16 ≤2
MIC values are presented in µg/mL; Gr.: Group

Citation: Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, et al. (2015) Effect of Bioeld Energy Treatment on Streptococcus group B: A
Postpartum Pathogen. J Microb Biochem Technol 7: 269-273. doi:10.4172/1948-5948.1000223
Volume 7(5): 269-273 (2015) - 272
J Microb Biochem Technol
ISSN: 1948-5948 JMBT, an open access journal
show any change in all the treated groups aer bioeld treatment as
compared to the control.
Identication of organism by biotype number
e species (S. agalactiae gr. B) was identied based on variety of
conventional biochemical characters and biotyping. Biotype number of
particular organism was evaluated aer interpreting the results of the
biochemical reactions. e biotype number then led to the particular
organism identication. In this experiment, biotyping was performed
using automated systems. Results showed changes of biotype numbers
in the bioeld treated Gr. II (on day 5 and 10) and Gr. III (on day
10) without alteration of organism. Based on the biochemical data,
biotype number was changed in treated Gr. II on day 5 (777777615,
S. agalactiae group B) and on day 10 (757677405, S. agalactiae group
B) with respect to the control (237147047) i.e. S. agalactiae group B
(Table 3). Biotyping, covers the overall cellular pattern of enzymatic
activities of any organism. GBS can be characterized based on analysis
of biochemical properties with CAMP, Na-hippurate positive and
esculin negative as key characters [25]. In this experiment, bile esculin
also showed negative (-) reaction in control sample, that directly
correlated with literature. is negative reaction of esculin was altered
aer bioeld treatment in revived treated cells of GBS. It was indicated
that bioeld treatment has the ability to alter the biochemical pattern
which may be due to change the enzymatic reaction. So, it is assumed
that these changes of biotype number without alteration in organism
may be due to change of metabolic and/or enzymatic reactions of GBS.
Bioeld treatment may responsible for alteration in microorganism
at genetic and/or enzymatic level, which probably act on receptor protein.
While altering receptor protein, ligand-receptor/protein interactions
may alter that could lead to dierent phenotypic characteristics [26].
Bioeld treatment might induce a signicant changes in revived
strain of GBS and altered the MIC values, biochemical reactions, and
ultimately change the biotype number of microorganism.
Conclusion
Altogether, the bioeld treatment has signicantly altered 70.37%,
(out of twenty-seven) the MIC values of tested antimicrobials against
the strain of S. agalactiae gr. B. Noroxacin was improved the MIC value
by two-fold (8 to ≤4 µg/mL) in Gr. II on day 10 aer bioeld energy
treatment as compared to the control. Additionally, it also signicantly
(48.28%) altered the biochemical reactions pattern of bioeld energy
treated strain of S. agalactiae gr. B. On the basis of utilization of group
B streptococcal specic biochemicals, change in metabolic reactions led
to variation of biotype number in all the treated groups without change
of organism aer bioeld treatment with respect to the control. Based
on above ndings, it is assumed that Mr. Trivedi’s bioeld treatment is
Table 2: Effect of bioeld treatment on Streptococcus agalactiae group B to the biochemical reaction pattern.
S. No. Code Biochemical Gr. I Type of Response
Gr. II Gr. III
Day 5 Day 10
1. ARA Arabinose - - - -
2. ARG Arginine + + - +
3. BAC Bacillosamine + + + +
4. BE Bile esculin - + + -
5. BL Beta lactamases NR NR NR NR
6. CV Crystal violet - + + -
7. HEM Hemolysin + + + +
8. IDX Indoxyl phosphatase + + + +
9. INU Inulin - - - -
10. LAC Acidication lactose + + + +
11. MAN Mannitol - + + -
12. MNS Mannose + + + +
13. MS Micrococcus screen + + + +
14. NaCl Sodium chloride - + + -
15. NIT Nitrate - + + -
16. NOV Novobiocin - + + -
17. OPT Optochin + + + +
18. PGR Glycosidase
*
+ + - +
19. PGT Glycosidases
#
+ + + +
20. PHO Phosphatase + + + +
21. PRV Pyruvate + - - +
22. PYR Pyrolidonyl arylamidase - + + -
23. RAF Rafnose - + - -
24. RBS Rambose + - - +
25. SOR Sorbitol - + - -
26. TFG Thymidine free growth + + + +
27. TRE Acidication trehalose + + + +
28. URE Urea - + + -
29. VP Voges-Proskauer + + + +
‘-’ (negative); ‘+’ (positive); Gr.: Group; NR: Not reported; *PGR: p-nitro phenyl β-D- glucuronide; #PGT: p-nitro phenyl β-D-galactopyranoside.

Citation: Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, et al. (2015) Effect of Bioeld Energy Treatment on Streptococcus group B: A
Postpartum Pathogen. J Microb Biochem Technol 7: 269-273. doi:10.4172/1948-5948.1000223
Volume 7(5): 269-273 (2015) - 273
J Microb Biochem Technol
ISSN: 1948-5948 JMBT, an open access journal
an alternative approach to alter the antibiogram prole of S. agalactiae
gr. B.
Acknowledgement
Authors gratefully acknowledged to Trivedi science, Trivedi testimonials and
Trivedi master wellness and the whole team of PD Hinduja National Hospital and
MRC, Mumbai, Microbiology Lab for their support.
References
1. Campbell JR, Hillier SL, Krohn MA, Ferrieri P, Zaleznik DF, et al. (2000) Group
B Streptococcal colonization and serotype-specic immunity in pregnant
women at delivery. Obstet Gynecol 96: 498-503.
2. Cowgill K, Taylor TH Jr, Schuchat A, Schrag S (2003) Report from the CDC.
Awareness of perinatal group B streptococcal infection among women of
childbearing age in the United States, 1999 and 2002. J Womens Health
(Larchmt) 12: 527-532.
3. Mullaney DM (2001) Group B streptococcal infections in newborns. J Obstet
Gynecol Neonatal Nurs 30: 649-658.
4. van der Poll T, Opal SM (2008) Host-pathogen interactions in sepsis. Lancet
Infect Dis 8: 32-43.
5. Ratner HB, Weeks LS, Stratton CW (1986) Evaluation of spot CAMP test for
identication of group B streptococci. J Clin Microbiol 24: 296-297.
6. Schuchat A, Wenger JD (1994) Epidemiology of group B streptococcal disease.
Risk factors, prevention strategies, and vaccine development. Epidemiol Rev
16: 374-402.
7. Jacobs MR, Kelly F, Speck WT (1982) Susceptibility of group B streptococci
to 16 beta-lactam antibiotics, including new penicillin and cephalosporin
derivatives. Antimicrob Agents Chemother 22: 897-900.
8. McCracken GH Jr, Ginsberg C, Chrane DF, Thomas ML, Horton LJ (1973)
Clinical pharmacology of penicillin in newborn infants. J Pediatr 82: 692-698.
9. Myers R (2003) The basics of chemistry. Greenwood Press, Westport,
Connecticut.
10. Movaffaghi Z, Farsi M (2009) Bioeld therapies: biophysical basis and biological
regulations? Complement Ther Clin Pract 15: 35-37.
11. Rivera-Ruiz M, Cajavilca C, Varon J (2008) Einthoven's string galvanometer:
the rst electrocardiograph. Tex Heart Inst J 35: 174-178.
12. Trivedi MK, Tallapragada RM (2008) A transcendental to changing metal
powder characteristics. Met Powder Rep 63: 22-28, 31.
13. Trivedi MK, Nayak G, Patil S, Tallapragada RM, Latiyal O (2015) Studies of
the atomic and crystalline characteristics of ceramic oxide nano powders after
Bioeld treatment. Ind Eng Manage 4: 161.
14. Dabhade VV, Tallapragada RR, Trivedi MK (2009) Effect of external energy
on atomic, crystalline and powder characteristics of antimony and bismuth
powders. Bull Mater Sci 32: 471-479.
15. Sances F, Flora E, Patil S, Spence A, Shinde V (2013) Impact of bioeld
treatment on ginseng and organic blueberry yield. Agrivita J Agric Sci 35: 22-29.
16. Lenssen AW (2013) Bioeld and fungicide seed treatment inuences on
soybean productivity, seed quality and weed community. Agricultural Journal
83: 138-143.
17. Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) Antimicrobial
sensitivity pattern of Pseudomonas uorescens after bioeld treatment. J Infect
Dis Ther 3: 222.
18. Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Phenotypic and
biotypic characterization of Klebsiella oxytoca: An impact of bioeld treatment.
J Microb Biochem Technol 7: 203-206.
19. Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) An effect of bioeld
treatment on multidrug-resistant Burkholderia cepacia: A multihost pathogen.
J Trop Dis 3: 167.
20. Patil SA, Nayak GB, Barve SS, Tembe RP, Khan RR (2012) Impact of bioeld
treatment on growth and anatomical characteristics of Pogostemon cablin
(Benth.). Biotechnology 11: 154-162.
21. Nayak G, Altekar N (2015) Effect of bioeld treatment on plant growth and
adaptation. J Environ Health Sci 1: 1-9.
22. Fader RC, Weaver E, Fossett R, Toyras M, Vanderlaan J, et al. (2013)
Multilaboratory study of the biomic automated well-reading instrument versus
MicroScan WalkAway for reading MicroScan antimicrobial susceptibility and
identication panels. J Clin Microbiol 51: 1548-1554.
23. Kaufhold A, Ferrieri P (1993) The microbiologic aspects, including diagnosis, of
beta-hemolytic streptococcal and enterococcal infections. Infect Dis Clin North
Am 7: 235-256.
24. Facklam RR, Thacker LG, Fox B, Eriquez L (1982) Presumptive identication of
streptococci with a new test system. J Clin Microbiol 15: 987-990.
25. Ekin IH, Gurturk K, Yaman G, Yesilova A (2010) Biotyping of nontypeable
Group B Streptococci. Van Vet J 21: 117-122.
26. Lindstrom E, Mild KH, Lundgren E (1998) Analysis of the T cell activation
signaling pathway during ELF magnetic eld exposure, p56
lck
and [Ca
2+
]
i
-measurements. Bioeletrochem Bioenerg 46: 129-137.
Table 3: Effect of bioeld treatment on biotype number of Streptococcus agalactiae group B.
Feature Gr. I Gr. II Gr. III
Day 5 Day 10 Day 10
Biotype 237147047 777777615 757677405 237147047
Organism Identication Streptococcus agalactiae group B Streptococcus agalactiae group B
(Very rare biotype)
Streptococcus agalactiae group B
(Very rare biotype)
Streptococcus agalactiae group B
Gr.: Group
OMICS International: Publication Benefits & Features
Unique features:
• Increasedglobalvisibilityofarticlesthroughworldwidedistributionandindexing
• Showcasingrecentresearchoutputinatimelyandupdatedmanner
• Specialissuesonthecurrenttrendsofscienticresearch
Special features:
• 700OpenAccessJournals
• 50,000editorialteam
• Rapidreviewprocess
• Qualityandquickeditorial,reviewandpublicationprocessing
• IndexingatPubMed(partial),Scopus,EBSCO,IndexCopernicusandGoogleScholaretc
• SharingOption:SocialNetworkingEnabled
• Authors,ReviewersandEditorsrewardedwithonlineScienticCredits
• Betterdiscountforyoursubsequentarticles
Submityourmanuscriptat:http://www.editorialmanager.com/jmbt
Citation: Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, et al. (2015)
Effect of Bioeld Energy Treatment on Streptococcus group B: A Postpartum
Pathogen. J Microb Biochem Technol 7: 269-273. doi:10.4172/1948-
5948.1000223